GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Price-to-Tangible-Book

Tryptamine Therapeutics (ASX:TYP) Price-to-Tangible-Book : 1.96 (As of May. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Price-to-Tangible-Book?

As of today (2024-05-27), Tryptamine Therapeutics's share price is A$0.0275. Tryptamine Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was A$0.01. Hence, Tryptamine Therapeutics's Price to Tangible Book Ratio of today is 1.96.

The historical rank and industry rank for Tryptamine Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

ASX:TYP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91   Med: 4.75   Max: 8.58
Current: 2.75

During the past 6 years, Tryptamine Therapeutics's highest Price to Tangible Book Ratio was 8.58. The lowest was 0.91. And the median was 4.75.

ASX:TYP's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.8 vs ASX:TYP: 2.75

A closely related ratio is called PB Ratio. As of today, Tryptamine Therapeutics's share price is A$0.0275. Tryptamine Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was A$0.02. Hence, Tryptamine Therapeutics's P/B Ratio of today is 1.83.


Tryptamine Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Tryptamine Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Price-to-Tangible-Book Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Tangible-Book
Get a 7-Day Free Trial 6.87 5.07 4.75 2.42 0.91

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 7.42 2.42 2.33 0.91 1.96

Competitive Comparison of Tryptamine Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Tryptamine Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tryptamine Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Price-to-Tangible-Book falls into.



Tryptamine Therapeutics Price-to-Tangible-Book Calculation

Tryptamine Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.0275/0.014
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Tryptamine Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics (ASX:TYP) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines